RxDoctor Payments Data

Vinni Makin, MD

Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1427233675

Payments from drug & device makers

$19,490in general payments, 2019–2025

Across 56 payments — averaging $348.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$14K
  • Novo Nordisk$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$333
  • Lilly USA, LLC$319
  • Averitas Pharma Inc.$186
  • Sanofi-aventis U.S. LLC$55
  • plus $132 from 6 others

What the payments were for

  • Consulting fees$4,20922%
  • Speaking & faculty fees$11,80161%
  • Travel & lodging$2,02410%
  • Food & beverage$1,4437%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,490 in reported general payments places this provider in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$24,027
Medicare patients
168
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$89,961
TrulicityDulaglutide25$46,332
JardianceEmpagliflozin24$38,666
MounjaroTirzepatide23$31,606
FarxigaDapagliflozin Propanediol17$19,679
Testosterone12$6,314
SynthroidLevothyroxine Sodium61$5,489
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,086
Levothyroxine Sodium242$2,314
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,408
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$963
Metformin Hcl ErMetformin Hcl83$951
Desmopressin AcetateDesmopressin (Nonrefrigerated)11$871
Hydrocortisone16$774
Rosuvastatin Calcium11$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$4,923$89,96152 claims
Lilly USA, LLCTrulicity, Mounjaro$319$77,93748 claims
AstraZenecaFarxiga$17$19,67917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →